FDA Approves Pioneering Gene Therapy for Rare Childhood Deafness

The Food and Drug Administration approved Regeneron’s Otarmeni on Thursday, marking the first gene therapy for genetic hearing loss. This treatment targets a rare form caused by the OTOF gene mutation, affecting about 50 babies born in the U.S. each year. Families now have an alternative to cochlear implants, which Dr. Eliot Shearer described as “life-changing” for children with hearing loss.

Otarmeni replaces the faulty OTOF gene to produce the otoferlin protein, essential for transmitting sound signals from cochlear cells to nerves. Without this protein, sound fails to reach the brain, leaving children deaf. The therapy delivers a single dose directly to the inner ear during a procedure similar to cochlear implant surgery.

A trial involved 20 children with the OTOF mutation who received the therapy in one or both ears. Results indicated hearing improved in 16 participants, with five able to detect whispers afterward. Common side effects included infection of the middle ear, vomiting, nausea, and dizziness, yet the therapy provides constant benefits without relying on batteries.

Regeneron will offer Otarmeni at no cost to U.S. patients, addressing potential treatment expenses. The approval came through the Commissioner’s National Priority Voucher, a program designed to speed drug reviews for rare conditions. Sarah Emond noted that this approach ensures affordable access, contrasting with typical gene therapy costs that can reach millions.

One parent shared that their baby, born deaf, can now hear after the treatment, highlighting personal gains for families. This milestone shifts reliance from devices like cochlear implants, which alter sound quality, to a more natural solution. Children with restored hearing may engage more fully in school and social activities, reducing isolation for households.